- ICH GCP
- USA klinikai vizsgálatok nyilvántartása
- Klinikai vizsgálat NCT07749989
A Retrospective Analysis of Patients With Gastroesophageal Reflux Disease Based on a Prospective Clinical Dataset
2026. augusztus 5. frissítette: JunZhang, Beijing Friendship Hospital
Establishing an Innovative Cohort of Chinese Patients With Gastroesophageal Reflux Disease Based on the Prospective Database of the National Clinical Research Center for Digestive Diseases: A Retrospective Study
This retrospective, observational cohort study aimed to establish a comprehensive research cohort utilizing a large-scale prospective clinical registry.
The primary objectives were to characterize the real-world demographic profiles, clinical features, psychological characteristics, and treatment patterns of Chinese patients with gastroesophageal reflux disease (GERD), as well as to evaluate post-treatment improvements in both GERD symptoms and psychological well-being.
The study retrospectively enrolled approximately 5,000 patients with a confirmed diagnosis of GERD, with data derived from the prospective registry of the National Clinical Research Center for Digestive Diseases.
Investigators systematically extracted data on baseline demographics, clinical presentations, objective diagnostic findings, preoperative psychological status, surgical complications, and longitudinal follow-up outcomes for all eligible patients.
Ultimately, this study sought to provide high-quality, China-specific evidence to inform the precise phenotyping of GERD and to guide standardized, individualized clinical decision-making.
A tanulmány áttekintése
Állapot
Toborzás
Körülmények
Beavatkozás / kezelés
Tanulmány típusa
Megfigyelő
Beiratkozás (Becsült)
5000
Kapcsolatok és helyek
Ez a rész a vizsgálatot végzők elérhetőségeit, valamint a vizsgálat lefolytatásának helyére vonatkozó információkat tartalmazza.
Tanulmányi kapcsolat
- Név: Zhi zheng, Attending surgon
- Telefonszám: +86-13811132175
- E-mail: zhengzhi@ccmu.edu.cn
Tanulmányi helyek
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, Kína, 100050
- Toborzás
- Beijing Friendship hospital, Capital Medical University
-
Kapcsolatba lépni:
- Zhi zheng, Attending surgon
- Telefonszám: +86-13811132175
- E-mail: zhengzhi@ccmu.edu.cn
-
-
Részvételi kritériumok
A kutatók olyan embereket keresnek, akik megfelelnek egy bizonyos leírásnak, az úgynevezett jogosultsági kritériumoknak. Néhány példa ezekre a kritériumokra a személy általános egészségi állapota vagy a korábbi kezelések.
Jogosultsági kritériumok
Tanulmányozható életkorok
- Felnőtt
- Idősebb felnőtt
Egészséges önkénteseket fogad
Nem
Mintavételi módszer
Nem valószínűségi minta
Tanulmányi populáció
The study population will be drawn from the clinical registry of the National Clinical Research Center for Digestive Diseases at Beijing Friendship Hospital, Capital Medical University.
This retrospective cohort study will enroll approximately 5,000 patients with a confirmed diagnosis of gastroesophageal reflux disease (GERD).
During the study period, all eligible patients documented in the registry who meet the inclusion criteria will be consecutively enrolled.
The source population comprises patients presenting to Beijing Friendship Hospital for the diagnosis and management of GERD.
This registry encompasses comprehensive data on clinical symptoms, objective diagnostic findings, treatment details, and longitudinal follow-up outcomes for all enrolled individuals.
As Beijing Friendship Hospital is a major tertiary referral center in China serving a broad geographical catchment area, the study cohort is anticipated to be highly representative of diverse patient demographics and clinical
Leírás
Inclusion Criteria:
- Aged between 18 and 90 years old.
- Patients were required to present with at least one typical symptom of gastroesophageal reflux disease (GERD)-such as heartburn, regurgitation, or non-cardiac chest pain-and to have presented to Beijing Friendship Hospital for the evaluation and management of these symptoms.
- Received treatment, including pharmacological therapy and anti-reflux surgery, at Beijing Friendship Hospital.
- Voluntary signing of informed consent, agreeing to the use of clinical information for future research.
Exclusion Criteria:
- Female patients who were pregnant or lactating.
- Patients with significantly incomplete or missing critical clinical data.
- Patients with an equivocal or unconfirmed diagnosis of GERD.
- Current neurologic or cognitive impairment, which would preclude ability to obtain informed consent.
- Refusal to participate in the study.
Tanulási terv
Ez a rész a vizsgálati terv részleteit tartalmazza, beleértve a vizsgálat megtervezését és a vizsgálat mérését.
Hogyan készül a tanulmány?
Tervezési részletek
Kohorszok és beavatkozások
Csoport / Kohorsz |
Beavatkozás / kezelés |
|---|---|
|
GERD Retrospective Cohort
A retrospective cohort of approximately 5,000 patients with a confirmed diagnosis of gastroesophageal reflux disease (GERD) treated at Beijing Friendship Hospital was established using data extracted from the prospective clinical registry of the National Clinical Research Center for Digestive Diseases.
|
Data on clinical symptoms, treatment details, and long-term follow-up outcomes were retrospectively extracted from electronic medical records (EMRs) and institutional databases.
|
Mit mér a tanulmány?
Elsődleges eredményintézkedések
Eredménymérő |
Intézkedés leírása |
Időkeret |
|---|---|---|
|
Pre- and Post-Treatment Improvement in GERD-HRQL Scores
Időkeret: From pre-treatment to up to 10 years post-treatment
|
The Gastroesophageal Reflux Disease Health-Related Quality of Life (GERD-HRQL) questionnaire is utilized to assess patient outcomes as a quantitative variable.
The scale comprises 11 items, each scored from 0 to 5, with higher scores indicating a better quality of life (QoL).
Clinical success is defined as a >50% reduction in the total symptom score.
|
From pre-treatment to up to 10 years post-treatment
|
Másodlagos eredményintézkedések
Eredménymérő |
Intézkedés leírása |
Időkeret |
|---|---|---|
|
Helicobacter pylori Infection Status
Időkeret: From 30 days prior to surgery to 10 years post-surgery
|
Helicobacter pylori infection status determined by ¹³C/¹⁴C urea breath test.
|
From 30 days prior to surgery to 10 years post-surgery
|
|
Pre- and Post-Treatment Improvement in GERD-Q Scores
Időkeret: From pre-treatment to up to 10 years post-treatment
|
The Gastroesophageal Reflux Disease Questionnaire (GERD-Q) is utilized to evaluate GERD symptoms.
The total score ranges from 0 to 18, with higher scores indicating greater symptom severity.
|
From pre-treatment to up to 10 years post-treatment
|
|
Pre- and Post-Treatment Improvement in GSAS Scores
Időkeret: From pre-treatment to up to 10 years post-treatment
|
The GERD Symptom Assessment Scale (GSAS) is employed to evaluate GERD symptoms.
The total score ranges from 0 to 45, with higher scores indicating greater symptom severity.
|
From pre-treatment to up to 10 years post-treatment
|
|
Pre- and Post-Treatment Improvement in GIQLI Scores
Időkeret: From pre-treatment to up to 10 years post-treatment
|
The Gastrointestinal Quality of Life Index (GIQLI) is utilized to assess quality of life in patients with gastrointestinal diseases.
It comprises five subscales with a total score ranging from 0 to 144.
Higher scores indicate a better quality of life and superior therapeutic efficacy.
|
From pre-treatment to up to 10 years post-treatment
|
|
Pre- and Post-Treatment Improvement in EHAS Scores
Időkeret: From pre-treatment to up to 10 years post-treatment
|
The Esophageal Hypervigilance and Anxiety Scale (EHAS) is utilized to assess esophageal-specific hypervigilance and anxiety.
It comprises two subscales with a total score ranging from 0 to 56, with higher scores indicating more severe esophageal hypervigilance and anxiety.
|
From pre-treatment to up to 10 years post-treatment
|
|
Pre- and Post-Treatment Improvement in HADS Scores
Időkeret: From pre-treatment to up to 10 years post-treatment
|
The Hospital Anxiety and Depression Scale (HADS) is employed to evaluate patient anxiety and depression.
It comprises two subscales with a total score ranging from 0 to 42, with higher scores indicating more severe states of anxiety and depression.
|
From pre-treatment to up to 10 years post-treatment
|
|
Esophagitis Severity
Időkeret: From pre-treatment to up to 10 years post-treatment
|
Evaluated via gastroscopy according to the Los Angeles (LA) classification.
|
From pre-treatment to up to 10 years post-treatment
|
|
Severity of Hiatal Hernia
Időkeret: From pre-treatment to up to 10 years post-treatment
|
Evaluated via gastroscopy according to the Hill classification.
|
From pre-treatment to up to 10 years post-treatment
|
|
Presence of Barrett's Esophagus
Időkeret: From pre-treatment to up to 10 years post-treatment
|
Evaluated via gastroscopy.
|
From pre-treatment to up to 10 years post-treatment
|
|
Acid Exposure Time (AET)
Időkeret: From pre-treatment to up to 10 years post-treatment
|
Quantified via pH-impedance monitoring.
AET serves as the primary and most reliable metric for diagnosing objective GERD and evaluating the true burden of acid reflux, >4% indicate abnormal acid reflux
|
From pre-treatment to up to 10 years post-treatment
|
|
Number of Reflux Episodes
Időkeret: From pre-treatment to up to 10 years post-treatment
|
Quantified via pH-impedance monitoring.
|
From pre-treatment to up to 10 years post-treatment
|
|
DeMeester Score
Időkeret: From pre-treatment to up to 10 years post-treatment
|
The DeMeester Composite Score quantifies the severity of Gastroesophageal Reflux Disease (GERD).
It is calculated from 24-hour ambulatory esophageal pH monitoring using six acid exposure parameters: percentage of total, upright, and supine time with pH < 4; total reflux episodes; episodes lasting > 5 minutes; and the duration of the longest episode.
Each parameter is scored using the formula SV = (X - A) / SD + 1, where X is the measured value, A is the healthy baseline mean, and SD is the baseline standard deviation.
The total score is the sum of these six values.
Minimum value: 0. Maximum value: No fixed upper limit (unbounded).
In clinical applications, higher scores indicate more severe pathological acid exposure.
|
From pre-treatment to up to 10 years post-treatment
|
|
Symptom Index (SI)
Időkeret: From pre-treatment to up to 10 years post-treatment
|
Derived from pH-impedance monitoring to determine the temporal correlation between symptom events and reflux episodes, confirming whether a patient's symptoms are specifically reflux-driven.
An SI of ≥ 50% is universally considered positive, indicating a clinically meaningful symptom-reflux association.
|
From pre-treatment to up to 10 years post-treatment
|
|
Symptom Reflux Index (SRI)
Időkeret: From pre-treatment to up to 10 years post-treatment
|
Derived from pH-impedance monitoring to provide statistical validation of the symptom-reflux association, which is crucial for accurately phenotyping functional versus organic GERD.
An SRI of ≥ 95% (often utilized interchangeably with Symptom Association Probability, SAP) is considered positive, providing strong statistical evidence that symptoms are not occurring by chance.
|
From pre-treatment to up to 10 years post-treatment
|
|
Esophagogastric Junction (EGJ) Expiratory Pressure
Időkeret: From pre-treatment to up to 10 years post-treatment
|
Measured via high-resolution manometry (HRM).
|
From pre-treatment to up to 10 years post-treatment
|
|
Integrated Relaxation Pressure (IRP)
Időkeret: From pre-treatment to up to 10 years post-treatment
|
Measured via high-resolution manometry (HRM).
|
From pre-treatment to up to 10 years post-treatment
|
|
Esophagogastric Junction (EGJ) Morphology
Időkeret: From pre-treatment to up to 10 years post-treatment
|
Evaluated via high-resolution manometry (HRM) to assess hiatal hernia status.
|
From pre-treatment to up to 10 years post-treatment
|
|
Distal Latency (DL)
Időkeret: From pre-treatment to up to 10 years post-treatment
|
Measured via high-resolution manometry (HRM).
|
From pre-treatment to up to 10 years post-treatment
|
|
Distal Contractile Integral (DCI)
Időkeret: From pre-treatment to up to 10 years post-treatment
|
Measured via high-resolution manometry (HRM).
|
From pre-treatment to up to 10 years post-treatment
|
|
Esophageal Motility Type
Időkeret: From pre-treatment to up to 10 years post-treatment
|
Evaluated via high-resolution manometry (HRM) according to the Chicago classification.
|
From pre-treatment to up to 10 years post-treatment
|
|
Hiatal Hernia Size
Időkeret: From pre-treatment to up to 10 years post-treatment
|
Evaluated via computed tomography (CT).
|
From pre-treatment to up to 10 years post-treatment
|
|
Acid-Suppressive Medication Regimen
Időkeret: From enrollment to the end of treatment, assessed up to 12 weeks
|
This encompasses the specific medication name, prescribed dosage, and administration frequency.
|
From enrollment to the end of treatment, assessed up to 12 weeks
|
|
Operation Time
Időkeret: At the time of surgery
|
At the time of surgery
|
|
|
Blood Loss
Időkeret: At the time of surgery
|
At the time of surgery
|
|
|
Abdominal Drainage Fluid Volume
Időkeret: From treatment to 30 days after surgery
|
From treatment to 30 days after surgery
|
|
|
Total Duration of Hospitalization
Időkeret: From treatment to 30 days after surgery
|
From treatment to 30 days after surgery
|
|
|
Incidence of Postoperative Complications
Időkeret: From treatment to 30 days after surgery
|
From treatment to 30 days after surgery
|
Együttműködők és nyomozók
Itt találhatja meg a tanulmányban érintett személyeket és szervezeteket.
Szponzor
Tanulmányi rekorddátumok
Ezek a dátumok nyomon követik a ClinicalTrials.gov webhelyre benyújtott vizsgálati rekordok és összefoglaló eredmények benyújtásának folyamatát. A vizsgálati feljegyzéseket és a jelentett eredményeket a Nemzeti Orvostudományi Könyvtár (NLM) felülvizsgálja, hogy megbizonyosodjon arról, hogy megfelelnek-e az adott minőség-ellenőrzési szabványoknak, mielőtt közzéteszik őket a nyilvános weboldalon.
Tanulmány főbb dátumok
Tanulmány kezdete (Tényleges)
2026. április 17.
Elsődleges befejezés (Becsült)
2027. április 1.
A tanulmány befejezése (Becsült)
2027. május 1.
Tanulmányi regisztráció dátumai
Először benyújtva
2026. július 31.
Először nyújtották be, amely megfelel a minőségbiztosítási kritériumoknak
2026. augusztus 5.
Első közzététel (Tényleges)
2026. augusztus 6.
Tanulmányi rekordok frissítései
Utolsó frissítés közzétéve (Tényleges)
2026. augusztus 6.
Az utolsó frissítés elküldve, amely megfelel a minőségbiztosítási kritériumoknak
2026. augusztus 5.
Utolsó ellenőrzés
2026. augusztus 1.
Több információ
A tanulmányhoz kapcsolódó kifejezések
Kulcsszavak
További vonatkozó MeSH feltételek
Egyéb vizsgálati azonosító számok
- 2026-P2-209-01
Terv az egyéni résztvevői adatokhoz (IPD)
Tervezi megosztani az egyéni résztvevői adatokat (IPD)?
NEM
Gyógyszer- és eszközinformációk, tanulmányi dokumentumok
Egy amerikai FDA által szabályozott gyógyszerkészítményt tanulmányoz
Nem
Egy amerikai FDA által szabályozott eszközterméket tanulmányoz
Nem
Ezt az információt közvetlenül a clinicaltrials.gov webhelyről szereztük be, változtatás nélkül. Ha bármilyen kérése van vizsgálati adatainak módosítására, eltávolítására vagy frissítésére, kérjük, írjon a következő címre: register@clinicaltrials.gov. Amint a változás bevezetésre kerül a clinicaltrials.gov oldalon, ez a webhelyünkön is automatikusan frissül. .